Emerging Treatments for Indolent Lymphomas: The Role of the Oncology Pharmacist in Treatment and Toxicity Management

This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2022.

Program Description

Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are subtypes of B-cell non-Hodgkin lymphomas, which have similar treatment recommendations. Therapy options include observation, systemic cytotoxic chemotherapy, anti-CD20−targeted therapy, and oral therapies, with the treatment landscape changing to include more recently developed CD-19-directed therapies and antibody-drug conjugates. Therapy decisions are based on patient- and disease-specific factors, including genetic and molecular features. As pharmacists are involved in caring for patients with FL and MZL, they need to be familiar with recent clinical data and guideline recommendations. This program will feature case discussions from expert faculty, highlighting clinical pearls and the latest updates in practice.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 15, 2022
Expiration date: April 15, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Employ the most recent clinical data and guideline recommendations to personalize treatment for patients with follicular lymphoma (FL) or marginal zone lymphoma (MZL)
• Differentiate oral oncolytics, CD19-directed therapies, and bispecific antibodies for the treatment of FL and MZL based on pharmacology and adverse effect profiles
• Determine strategies to mitigate adverse effects and optimize care for patients receiving treatment with oral oncolytics, CD19-directed therapy, or bispecific antibodies

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-161-H01-P. The activity is available for CE credit through April 15, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, watch the symposium in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Karen M. Fancher, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: AstraZeneca Pharmaceuticals, BTG Specialty Pharmaceuticals, G1 Therapeutics, Merck & Co

Speakers Bureau: G1 Therapeutics

Kelly Valla, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose:

Speakers Bureau: BeiGene

Jordan Miller, PharmD, BCPS, BCOP, CPP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Taylor, PharmD, CPP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms